Detection of novel biomarkers of liver cirrhosis by proteomic analysis

Christian Mölleken, Barbara Sitek, Corinna Henkel, Gereon Poschmann, Bence Sipos, Sebastian Wiese, Bettina Warscheid, Christoph Broelsch, Markus Reiser, Scott L. Friedman, Ida Tornøe, Anders Schlosser, Günter Klöppel, Wolff Schmiegel, Helmut E. Meyer, Uffe Holmskov, Kai Stühler – 27 March 2009 – Hepatic cirrhosis is a life‐threatening disease arising from different chronic liver disorders. One major cause for hepatic cirrhosis is chronic hepatitis C. Chronic hepatitis C is characterized by a highly variable clinical course, with at least 20% developing liver cirrhosis within 40 years.

Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C

Damien Lucidarme, Juliette Foucher, Brigitte Le Bail, Julien Vergniol, Laurent Castera, Clotilde Duburque, Gérard Forzy, Bernard Filoche, Patrice Couzigou, Victor de Lédinghen – 27 March 2009 – The purpose of this study was to assess the influence of success rate and interquartile range on the accuracy of transient elastography for the diagnostic of fibrosis in hepatitis C virus infection. Two‐hundred fifty‐four consecutive patients had liver stiffness measurements and liver biopsy of at least 15 mm.

Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium‐90 microspheres

Ahsun Riaz, Laura Kulik, Robert J. Lewandowski, Robert K. Ryu, Georgia Giakoumis Spear, Mary F. Mulcahy, Michael Abecassis, Talia Baker, Vanessa Gates, Ritu Nayar, Frank H. Miller, Kent T. Sato, Reed A. Omary, Riad Salem – 27 March 2009 – We present the correlation between radiologic and pathologic findings in HCC patients who underwent radioembolization with yttrium‐90 (90Y) microspheres prior to resection or transplantation. Thirty‐five patients with a total of 38 lesions who underwent liver explantation after 90Y radioembolization were studied.

High expression of the bile salt‐homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis

Frank G. Schaap, Niels A. van der Gaag, Dirk J. Gouma, Peter L. M. Jansen – 27 March 2009 – Fibroblast growth factor 19 (FGF19) is an endocrine factor produced by the small intestine in response to uptake of luminal bile salts. In the liver, FGF19 binds to FGF receptor‐4, resulting in down‐regulation of cytochrome P (CYP) 7A1 and reduced bile salt synthesis.

MicroRNA‐101 regulates expression of the v‐fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma

Shuai Li, Hanjiang Fu, Yulan Wang, Yi Tie, Ruiyun Xing, Jie Zhu, Zhixian Sun, Lixin Wei, Xiaofei Zheng – 27 March 2009 – MicroRNAs (miRNAs) have recently been proposed as a versatile class of molecules involved in regulation of various biological processes. Although there is emerging evidence that some microRNAs can function as oncogenes or tumor suppressors, the specific role of miRNA in human hepatocellular carcinoma (HCC) is unclear at this point.

Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus‐1–hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy

Sharon R. Lewin, Ruy M. Ribeiro, Anchalee Avihingsanon, Scott Bowden, Gail Matthews, Pip Marks, Stephen A. Locarnini, Kiat Ruxrungtham, Alan S. Perelson, Gregory J. Dore – 27 March 2009 – Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus‐1 (HIV‐1) and hepatitis C virus.

Twenty years' follow‐up of portal vein conduits in liver transplantation

Dmitriy Nikitin, Linda W. Jennings, Tariq Khan, Sugam Vasani, Richard Ruiz, Edmund Q. Sanchez, Srinath Chinnakotla, Marlon F. Levy, Robert M. Goldstein, Goran B. Klintmalm – 26 March 2009 – Portal vein problems remain a formidable challenge in liver transplantation. In select situations, a portal vein conduit can provide a solution. No long‐term results have been reported.

Technique and outcome of autologous portal Y‐graft interposition for anomalous right portal veins in living donor liver transplantation

Shin Hwang, Sung‐Gyu Lee, Chul‐Soo Ahn, Ki‐Hun Kim, Deok‐Bog Moon, Tae‐Yong Ha, Gi‐Won Song, Dong‐Hwan Jung, Je‐Ho Ryu, Kyung‐Hoon Ko, Nam‐Kyu Choi, Kwan‐Woo Kim – 26 March 2009 – This study was intended to describe in detail the surgical technique and long‐term outcome of autologous portal vein (PV) Y‐graft interposition for adult living donor liver transplantation (LDLT). We assessed the outcome of 841 patients who underwent right lobe LDLT from January 2002 to December 2007 with respect to the reconstruction of double‐graft PVs.

Subscribe to